TABLE 1.
Panel of HIV-1 peptides, HLA restriction, and frequency of positive individualsa
| HIV gene product | Peptideb | No. of positive individuals/no. of individuals tested (%) |
|---|---|---|
| gag | B8-D/EIYKRWII | 2/2 (100) |
| B35-PPIPVGDIY | 2/3 (67) | |
| B57-I/LSPRTLNAWL | 2/4 (50) | |
| B8-GGKKKYR/KL | 1/2 (50) | |
| B57/B5801-KAFSPEVIPMF | 3/7 (43) | |
| A3-KIRLRPGGK | 1/3 (33) | |
| B14/Cw8-RAEQAS/TQEV | 1/3 (33) | |
| B14/Cw8-DRFF/YKTLRA | 1/3 (33) | |
| A2-TLNAWVKVI/V | 4/13 (31) | |
| Cw4-QASQEVKNW | 2/7 (29) | |
| B57/B5801-TSTLQEQIG/AW | 2/7 (29) | |
| B7/B42-GPGHKARVL | 3/12 (25) | |
| B18/B49-FRDYVDRFY/FK | 1/5 (20) | |
| B53-QATQEVKNW | 1/5 (20) | |
| B7/B8101-ATPQDLNTM | 1/6 (17) | |
| A2-SLF/YNTVATL | 2/13 (15) | |
| B53-TPQDLNM/TML | 2/13 (15) | |
| B53-AS/TQEVKNWM | 0/5 (0) | |
| B53 VKNWMTETLL | 0/5 (0) | |
| A24/B44-RDYVDRFY/FKTL | 0/9 (0) | |
| Cw4-KYRLKHLVW | 0/9 (0) | |
| A26-YVDRFFKTL | 0/1 (0) | |
| B7-SPRTLNAWV | 0/4 (0) | |
| A1-GSEELRSLY | 0/5 (0) | |
| A30-RSLYNTVATLY | 0/16 (0) | |
| B14/Cw8-DLNM/TMLNI/TV | 0/3 (0) | |
| A25/B53-D/ETINEEAAEW | 0/6 (0) | |
| pol | B35-H/NPDIVIYQY | 2/3 (67) |
| Cw8-VTDSQYALGI | 1/2 (50) | |
| B8-GPKVKQWPL | 1/2 (50) | |
| A6802/A74-ITLWQRPLV | 6/13 (46) | |
| B45-GAETFYVDGA | 3/7 (43) | |
| B35-EPIVGAETFY | 2/5 (40) | |
| A6802/A74-ETFYVDGAAN | 5/13 (38) | |
| B57-KITTESIVIW | 1/3 (33) | |
| A6802-ETAYFILKL | 3/9 (33) | |
| A2-VIYQYMDDL | 3/12 (25) | |
| A3/A11/A33-A/SIFQSSMTK | 1/4 (25) | |
| A6802-DTVLEEMNL | 2/9 (22) | |
| A30-KLNWASQIY | 2/13 (15) | |
| B57/B5801-IVLPEKDSW | 1/7 (14) | |
| A2-ILKE/DPVHGV | 1/13 (8) | |
| A30-KQNPDIVIYQY | 1/15 (7) | |
| A3/A11/A31/A33-DLEIGQHRTK | 0/5 (0) | |
| A6802-DVTLEDINL | 0/9 (0) | |
| env | B14-ERYLKDQQL | 1/1 (100) |
| A29-FNCGGEFFY | 5/8 (63) | |
| Cw8-NCSFNISTSI | 1/2 (50) | |
| B35-TA/NPWNA/SSW | 1/3 (33) | |
| A24/B8-YLR/KDQQLL | 2/7 (29) | |
| A3/A31-RLRDLLLIVTR | 1/4 (25) | |
| B15/Cw4-SFNCGGEFF | 3/17 (18) | |
| A30-IVNRVRQGY | 1/16 (6) | |
| A3-TVYYGVPVWK | 0/3 (0) | |
| A30-KYCWNLLQY | 0/16 (0) | |
| B7-IPRRIRQGL | 0/4 (0) | |
| nef | B35-VPLRPMTY | 3/3 (100) |
| Cw8-KAAVDLSMFL | 2/2 (100) | |
| A3-QVPLRPMTYK | 2/3 (67) | |
| B42-TPQVPLRPM | 5/10 (50) | |
| B7/B42/B8101-TPGPGI/VRYPL | 2/4 (50) | |
| B18/B49-YPLTFGWCY/F | 2/5 (40) | |
| A2-PLTFGWCYKL | 3/11 (27) | |
| A3-DLSHFLKEK | 1/5 (20) | |
| B8-FLKEKGGL | 2/11 (18) | |
| A2-VLEWRFDSRL | 1/11 (9) | |
| A2-ALKHRAYEL | 1/12 (8) | |
| B7-FPVTPQVPLR | 0/4 (0) | |
| A24-DSRLAFHHM | 0/5 (0) | |
| rev | A1-ISTERILSTY | 1/5 (25) |
a
Expressed as the number of babies with a positive peptide response over the number of infants tested with that peptide, followed by the percent. Assays were conducted at multiple ages per infant, and thus responses to a given peptide were counted once per infant if there was ever detection of a response with a particular peptide. Peptides that stimulated positive responses in ≥50% of infants are indicated in boldface.
b
HLA restriction of each peptide precedes the sequence. Clade variants are indicated by a slash within the amino acid sequence